From the Wires
Neuralstem Reports Third Quarter Financial Results And Provides Update On Clinical Programs And Business Highlights
By: PR Newswire
Nov. 9, 2012 09:18 AM
ROCKVILLE, Md., Nov. 9, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) reported its financial results for the three months and nine months ended September 30, 2012 and provided an update on clinical programs and business highlights.
"In the third quarter, the company achieved three significant clinical milestones. The first was the completion of the eighteenth and final surgery in our ALS Phase I trial. All ALS trial assessments show the NSI-566 neural stem cells and intraspinal transplantation procedure, the first in the world, to be safe. The trial's principal investigator, Dr. Eva Feldman, said she believes we are seeing evidence of a treatment effect in some Phase I patients over a sustained period of time. We look forward to advancing to the next ALS trials, to increase both number of patients treated and NSI-566 dosage, and effectively evaluate efficacy. To that end, we are working diligently with our investigators to file an IND with the FDA for a Phase II ALS trial by year-end," said Karl Johe, PhD, Chairman of Neuralstem's Board of Directors and Chief Scientific Officer.
"The second significant clinical milestone was approval to begin our ischemic stroke trial in China. Our collaborators in Beijing, at the world-class BaYi Brain Hospital are on schedule to start enrollment early in the first quarter for a combined Phase I/II clinical trial to treat motor deficits due to ischemic stroke with NSI-566. The first part of the study, Phase I, will be open-label and enroll up to 18 patients who will be assigned to one of three cohorts. Each cohort will receive ascending doses of NSI-566 directly into the brain at the stroke area (another first for Neuralstem), to define the maximal safe dose, before proceeding to the Phase II/proof-of-concept study to evaluate efficacy," said Dr. Johe. "One of several independent Neuralstem studies presented at The Society for Neuroscience's annual meeting demonstrated significant recovery of motor and neurological functions in ischemic stroke rats with NSI-566; a second ischemic stroke study demonstrated safety and feasibility in a chronic model in mini-pigs. Together, with the extensive human safety data established in our ALS trial, these two studies demonstrate strong proof-of-principle data that our NSI-566 cells are ready to test in humans to treat paralysis in stroke patients. A rat spinal cord injury study, reported in the peer-reviewed scientific journal CELL, demonstrated that NSI-566 cells induce regeneration of injured spinal cord axons into the graft and serve as a bridge to reconnect to gray matter motor neurons for many spinal cord segments below an injury, inducing significant recovery of motor functions."
Dr. Johe concluded: "The third significant clinical milestone was the FDA approval for dosing the second cohort of major depressive disorder patients in the Phase Ib trial of NSI-189. Our lead neurogenic drug, NSI-189 is a first-in-class orally active drug that stimulates new neuron growth and increased volume in the hippocampus, which we believe can help patients with MDD and other psychological and cognitive conditions. We are on track to complete the Ib, an ascending-dose, 28-day-cycle safety trial designed in collaboration with Dr. Maurizio Fava of Harvard University and Massachusetts General, during the first quarter of 2013."
Neuralstem's President and CEO Richard Garr added: "The third quarter of 2012 marked business milestones as well. We saw a major addition to our patent estate with U.S. patent number 8,236,299, with a patent life into 2030, titled: 'Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions.' This is significant in that it covers processes involved in our first potential transplantation product, including claims covering processes for dissociating our neural stem cells from central nervous system tissue; culturing the cells; expanding the cells in vitro and transplanting the cells into the spinal cord of a patient to treat a wide array of neurodegenerative conditions, including ALS."
Mr. Garr continued: "The company granted its first licenses for use of our proprietary Spinal Cord Delivery Platform and Floating Cannula. As the industry standard for delivering therapeutic agents to the spinal cord, we expect to continue to announce licenses of the surgical devices to both industry and academia as they now begin to explore the possibilities our technology has enabled. We are also continuing discussions for licensing and partnership opportunities for our neurogenic small molecule program, for which we are seeing strong interest. Our goal is to move NSI-189 and our preclinical library of additional novel neurogenic compounds forward in multiple indications, which range from Alzheimer's disease and anti-aging (nootropic) to chronic traumatic encephalopathy and post-traumatic stress disorder. We believe this can best be accomplished through partnering with industry."
Clinical Program and Business Highlights
Cellular Therapy: NSI-566 Phase I Clinical Trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University Hospital
Cellular Therapy: NSI-566 Phase I/II Clinical Trial in Ischemic Stroke at BaYi Brain Hospital
Cellular Therapy: NSI-566 Pre-clinical Programs
Neurogenic Small Molecule NSI-189: Phase I Clinical Trial in Major Depressive Disorder (MDD)
Third Quarter Financial Results
For the third quarter of 2012, the Company reported a net loss of $2,577,391 or $0.04 per share, compared with a net loss of $3,211,604 or $0.07 per share, for the comparable 2011 period. The decrease in net loss was primarily due to an approximately $698,000 reduction in project expenses related to studies which ended in 2011 coupled with a decrease in non-cash stock based compensation expense of approximately $181,000 partially offset by increases in consulting expenses. In addition, in the third quarter of 2012, the Company recognized approximately $171,000 in revenue from third-party licenses agreements.
For the nine months ended September 30, 2012, the Company reported a net loss of $7,406,553, or $0.14 per share, compared with a net loss of $9,962,131 or $0.21 per share for the comparable 2011 period. The decrease in net loss was primarily due to a reduction in non-cash stock based compensation expense of approximately $1,700,000 coupled with decreases of approximately $617,000 in project expenses and $355,000 in legal expenses and an increase in revenues of approximately $302,000 partially offset by gains of approximately $412,000 related to a legal settlement and changes in the fair value of certain warrant obligations in 2011.
Cash and cash equivalents on hand at September 30, 2012 totaled $9,873,395, compared with $2,352,013 at December 31, 2011. The approximately $7,521,000 increase in cash and cash equivalents over the nine months of 2012 was primarily due to approximately $13,685,000 of net proceeds from the issuance of common stock during the nine months ended September, 2012 partially offset by cash used in operations.
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently treated the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended September 30, 2012.
SOURCE Neuralstem, Inc.
SOA World Latest Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week